# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Cantor Fitzgerald analyst Ross Osborn maintains Sanara MedTech (NASDAQ:SMTI) with a Overweight and lowers the price target f...
Sanara MedTech (NASDAQ:SMTI) reported quarterly losses of $(0.03) per share which beat the analyst consensus estimate of $(0.13...
Companies Reporting Before The Bell • Bitcoin Depot (NASDAQ:BTM) is expected to report quarterly loss at $0.08 per share on re...
Cantor Fitzgerald analyst Ross Osborn reiterates Sanara MedTech (NASDAQ:SMTI) with a Overweight and maintains $49 price target.
As part of this agreement, Sanara has formed a new subsidiary, Sanara Collagen Peptides, LLC ("SCP"), and has issued 10...
Sanara MedTech Inc. Based in Fort Worth, Texas, Sanara MedTech Inc. ("Sanara," the "Company," "we," ...